New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
10:49 EDTRAD, AMAT, NAVB, AVEO, ODPHigh option volume stocks; ODP, NAVB, RAD, AVEO, AMAT
News For ODP;NAVB;RAD;AVEO;AMAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 13, 2014
16:04 EDTAMATApplied Materials reports backlog $2.92B at Q4 end, down 2% sequentially
Subscribe for More Information
16:03 EDTAMATApplied Materials reports Q4 adjusted gross margin 44.2%, up 220bps YoY
Subscribe for More Information
16:03 EDTAMATApplied Materials sees Q1 adjusted EPS 25c-29c, consensus 31c
Sees Q1 revenue in the range of flat to up 5% from the previous quarter. Q1 consensus $2.37B.
16:02 EDTAMATApplied Materials reports Q4 adjusted EPS 27c, consensus 27c
Reports Q4 revenue $2.26B, consensus $2.27B.
15:18 EDTAMATNotable companies reporting after market close
Subscribe for More Information
14:50 EDTRADLonestar Capital to shut down by mid-2015, WSJ reports
Subscribe for More Information
14:45 EDTRADLonestar capital to shut down, DJ reports
Subscribe for More Information
14:33 EDTAMATApplied Materials technical remarks before results
The shares have outperformed the broader averages in the last three months, trading up over 7%. We need to pull back to a longer time frame to get a clearer idea of the levels that could impact price following earnings. The most critical level is on the upside at $23. This area has been touched several times since May, but there hasn't been a strong enough fundamental catalyst to push the shares higher. If the news is stronger than already bullish expectations for the shares, a breakout above $23 would seem very likely. The 52-week high at $23.64 would also likely be taken out. Next resistance levels to watch as potential upside objectives would be at $24.32 and $25.94. The latter level hasn't been seen in over ten years. If the news isn't up to bullish expectations then the $21 level would be a first probable downside test. The $20 and $19 areas would be additional downside objectives with $19 having been important support over the course of the year.
10:16 EDTODPOffice Depot, OfficeMax stores to open at 6pm on Thanksgiving Day
Office Depot and OfficeMax retail stores will be open from 6-9 p.m. local time on Thanksgiving Day, Nov. 27, and will re-open on Black Friday, Nov. 28, at 8 a.m.
10:01 EDTAMATOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
04:31 EDTAMATApplied Materials upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
November 12, 2014
14:19 EDTAMATApplied Material volatility elevated into Q4 and holiday outlook
Subscribe for More Information
November 11, 2014
16:01 EDTAMATOptions Update; November 11, 2014
Subscribe for More Information
09:17 EDTAVEOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FMSA Holdings (FMSA), up 4.7% following third quarter results. ALSO HIGHER: AVEO Pharmaceuticals (AVEO), up 7.6% after entering agreement with Ophthotech (OPHT) to license tivozanib... Ophthotech is 2.1% higher in pre-market trading... Galena Biopharma (GALE), up 3.6% after first patient dosed in NeuVax and Herceptin combination Phase 2 trial... Yamana Gold (AUY), up 3% after being upgraded to Overweight from Neutral at HSBC... Ambac Financial (AMBC), up 3.1% after being upgraded to Neutral from Sell at MKM Partners... China Finance (JRJC), up 12.4% after announcing a new partnership with Great Wall Securities... Zynga (ZNGA), up 5.7% after being upgraded on mobile business growth at Jefferies... Fiat Chrysler (FCAU), up 2.2% after being initiated with a Conviction Buy at Goldman. DOWN AFTER EARNINGS: Applied Optoelectronics (AAOI), down 10.7%... Ekso Bionics (EKSO), down 2.2%. ALSO LOWER: Alibaba Group (BABA), down 1.6% following comments made by vice chairman Joseph Tsai in an interview.
07:31 EDTNAVBNavidea receives $1.1M PDUFA filing free refund for award of orphan drug status
Navidea Biopharmaceuticals announced it has received a $1.1M refund of the previously paid Prescription Drug User Fee Act filing fee related to the granting of orphan drug status of Lymphoseek injection in head and neck cancers. Lymphoseek was granted Orphan Drug Designation by the FDA in September 2014 for use in sentinel lymph node detection in patients with cancer of the head and neck. Additionally, Platinum Partners, Navidea’s major investor, reaffirmed its support of the company through the remaining $31.8M available under the previously announced line of credit. “We believe we have sufficient capital resources to attain our immediate goals and realize the full commercial potential for Lymphoseek,” said Rick Gonzalez, Navidea CEO. “We are in a position to manage our available cash with our expected growth in revenue and gross profit, our ability to further reduce our operating costs and, if needed, our access to capital under the line of credit from Platinum Partners.”
06:44 EDTAVEOAveo Pharmaceuticals enters into agreement with Ophthotech for VEGF
Subscribe for More Information
06:37 EDTAVEOOphthotech enters into with Aveo Pharmaceuticals to license tivozanib
Ophthotech (OPHT) has entered into an exclusive research and option agreement with Aveo Pharmaceuticals (AVEO) to license tivozanib, a small molecule vascular endothelial growth factor, or VEGF, tyrosine kinase inhibitor, for the treatment of non-oncologic conditions of the eye. Under the terms of the agreement, Ophthotech will pay an upfront fee of $500,000 for exclusive rights to investigate this compound’s potency and potential as an ocular formulation. Ophthotech is solely responsible for the ocular formulation and development of this compound, which will focus initially on a sustained release formulation as a treatment for the maintenance phase of wet AMD therapy. Under the agreement, upon completion of Ophthotech’s initial analysis, if Ophthotech elects to continue the development of an ocular formulation of this anti-VEGF therapy, Ophthotech will pay additional fees based upon Ophthotech’s submission of an Initial New Drug application and upon the demonstration of proof of concept in humans. If Ophthotech exercises its option for an exclusive worldwide license for the compound for ocular indications, Ophthotech will pay a license fee, and development, regulatory and sales-based milestones, if achieved, as well royalties on commercial sales.
November 7, 2014
10:01 EDTRADRite Aid, HealthSpot announce plans for walk-in stations
Rite Aid announced it has entered into an agreement with HealthSpot to provide healthcare services via private, walk-in HealthSpot stations inside select Rite Aid locations. Rite Aid will pilot the HealthSpot stations in the greater Akron/Canton, Cleveland and Dayton/Springfield markets.
07:31 EDTAMATApplied Materials near-term upside may be limited, says Piper Jaffray
Subscribe for More Information
07:15 EDTODPOffice Depot management to meet with Deutsche Bank
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use